Teladoc (TDOC) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since a chang ...

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly making materially false and misleading statements regarding its business and financial outlook during the specified class period from May 7, 2025, to August 5, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague PC on behalf of investors who acquired LifeMD shares during the class period [1][2]. - Investors have until October 27, 2025, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against LifeMD - LifeMD is accused of overstating its competitive position and raising its 2025 guidance without properly accounting for increasing customer acquisition costs, particularly in its RexMD segment and for obesity-related drugs like Wegovy and Zepbound [3]. - Following the revelation of the true facts, LifeMD's shares experienced a significant decline of 44%, equating to a drop of $5.31 per share in a single trading session [3].

FRANKLIN, NEW JERSEY / ACCESS Newswire / October 2, 2025 / Silver Scott today announced the upcoming release of its proprietary AI engine designed to transform patient intake and triage for AffordableTelehealthPlan.com, the company's new healthcare platform aimed at providing affordable, accessible care for millions of underserved Americans. The AI engine enables patients to describe their symptoms by text, voice, or video. ...

SAN FRANCISCO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- A federal securities fraud class action lawsuit has been filed in the Eastern District of New York against LifeMD, Inc. (NASDAQ: LFMD) and its executives. The lawsuit alleges that the telehealth company presented a misleadingly optimistic image of its financial health and growth prospects, which ultimately led to a dramatic stock price decline in August. The suit, Johnston v. LifeMD, Inc., is seeking to recover damages for investors that purchased LifeMD secu ...

"It wasn't just a blip." Tennis star Serena Williams delivers a surge in demand for the telehealth site Ro, after opening up about her 30-pound weight-loss experience in an ad for its services. https://t.co/V45OcbyJfO ...

CHONGQING, CHINA - MAY 04: In this photo illustration, the logo of Hims & Hers Health, Inc. is displayed on a smartphone screen, with the company's stock market performance and candlestick chart visible in the background, on May 4, 2025, in Chongqing, China. Hims & Hers is an American telehealth company that provides personalized healthcare products and services for mental health, dermatology, sexual wellness, and primary care through a direct-to-consumer platform. (Photo illustration by Cheng Xin/Getty Ima ...

Core Insights - LifeMD, Inc. has announced a collaboration with Novo Nordisk to provide Ozempic at a reduced price of $499 per month for eligible self-pay patients [1][2] - The integration with NovoCare Pharmacy allows access to all FDA-approved doses of Ozempic through LifeMD's virtual care platform [1][2] - The initiative aims to improve access to GLP-1 therapies for millions of Americans suffering from type 2 diabetes, a condition affecting approximately 36 million people in the U.S. [2][3] Company Overview - LifeMD is a leading provider of virtual primary care, offering telemedicine, laboratory and pharmacy services, and specialized treatment across over 200 conditions [4] - The company utilizes a vertically integrated digital care platform and a 50-state affiliated medical group to enhance access to high-quality and affordable care [4] Collaboration Details - The expanded collaboration with Novo Nordisk includes not only Ozempic but also Wegovy, enhancing LifeMD's ability to deliver competitive self-pay prices for FDA-approved GLP-1 therapies [2][3] - LifeMD's telehealth platform is also integrated with LillyDirect pharmacy to provide access to Zepbound (tirzepatide), further diversifying treatment options for patients [3]

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of LifeMD, Inc. (NASDAQ: LFMD). Shareholders who purchased shares of LFMD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/lifemd-inc-loss-submission-form/?id=169640&from=3 CLASS PERIOD: May 7, 2025 to Augus ...

SAN FRANCISCO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- A new federal securities fraud class action lawsuit has been filed against LifeMD, Inc. (NASDAQ: LFMD) and its executives. The suit alleges the telehealth company presented a misleadingly optimistic picture of its financial health and growth, ultimately resulting in a dramatic stock price decline in August. The action was filed in the Eastern District of New York. The lawsuit, Johnston v. LifeMD, Inc., focuses on the period between May 7, 2025, and August 5, ...

Core Insights - Artificial intelligence (AI) is significantly transforming various industries, particularly healthcare, by enhancing efficiency and improving patient outcomes [1][2]. Group 1: AI in Healthcare - The integration of generative and agentic AI is aiding healthcare professionals in making more accurate diagnoses and reducing administrative burdens, which is crucial given the high burnout rates among physicians, with 93% reporting regular burnout [2]. - AI is positioned to address the supply and demand imbalance in healthcare, especially with an aging population, by bridging the gap between efficiency and personalized care [2]. Group 2: Investment Opportunities - Companies utilizing AI to enhance healthcare outcomes are seen as potential investment opportunities, with specific stocks highlighted for their growth potential [3]. - Hims & Hers Health (HIMS) has experienced a 121% increase in stock value in 2025, attributed to its AI-driven telehealth services that streamline administrative tasks [4][5]. - Tempus AI (TEM) is leveraging AI for precision medicine and oncology, with a 128% stock increase in 2025, and is recognized for its contributions to drug discovery for major pharmaceutical companies [8][10][11]. - Boston Scientific (BSX) is using AI to improve medical device performance and has received FDA approval for a new treatment system, contributing to a 17% stock increase in 2025 [12][14].